Advaxis CEO issues statement to shareholders regarding recent common stock transition

Thomas A. Moore, chairman and CEO of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has issued the following statement to shareholders regarding the recent transition to the OTCQB from the OTCBB:

Dear Fellow Shareholders,

Over the last few days, attaining the Company's stock quote information has been extremely difficult. This is largely attributed to a move by our collective Market Makers to quote and trade the Company's shares on the OTC Markets platform instead of the OTCBB platform for economic reasons of their own. Due to this change, Advaxis' common stock quote was automatically transferred from the OTCBB to the OTCQB market. OTCQB listed companies are fully reporting companies with the U.S. Securities and Exchange Commission. This makes it easy for investors to identify companies that are current in their reporting obligations. Several hundred other companies have been similarly affected. Our clinical trials and other key business activities are proceeding well and are unaffected by this change.

Sincerely yours,

Thomas A. Moore
Chairman/CEO